Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
WILMINGTON, Del., April 14, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)?
- Did you purchase your shares between May 6, 2014 and February 23, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of PTC Therapeutics (“PTC” or the “Company”) (NASDAQ:PTCT) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the District of New Jersey on behalf of all persons or entities that purchased the common stock of PTC between May 6, 2014 and February 23, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you wish to serve as lead plaintiff, you must move the Court no later than May 2, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of PTC during the Class Period, or purchased shares prior to the Class Period and still hold PTC, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/ptc-therapeutics-inc-ptct.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
